Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Core Insights - Cognition Therapeutics, Inc. announced the publication of a Phase 2 study on zervimesine (CT1812) for mild-to-moderate Dementia with Lewy Bodies (DLB) in the journal Alzheimer's & Dementia, highlighting the unmet need for disease-modifying treatments in this area [1][2] Study Results - The Phase 2 SHIMMER study involved 130 adults with mild-to-moderate DLB, confirming zervimesine's safety and tolerability while showing improvements in behavioral, cognitive, functional, and movement domains [2][6] - Zervimesine treatment led to significant improvements in neuropsychiatric symptoms, cognitive fluctuations, and activities of daily living compared to placebo [3][4] - Most treatment-related adverse events were mild or moderate, consistent with previous clinical experiences [3] Future Developments - The U.S. FDA is scheduled to meet with Cognition in January 2026 to discuss the next clinical studies for zervimesine, focusing on clinically meaningful endpoints [4] - The SHIMMER study was supported by a grant from the National Institute on Aging totaling approximately $30 million [7] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related degenerative disorders of the central nervous system, with zervimesine as a lead candidate [8][9]